A Management Team With Global Experience

Our management team brings a wealth of experience from the biotech, pharmaceutical, human and animal health sectors – as well as first hand experience establishing, marketing and raising capital for a range of successful businesses in Australia, Asia and the US. What they all have in common is a shared belief in the future of the diagnostic testing market and a joint commitment to the ongoing success of Genetic Technologies.

Dr Paul Kasian, BSc, PhD, MBA, GAICD
Chief Executive Officer

Dr Kasian was appointed as acting Chief Executive Officer on February 6, 2018. Dr Kasian has held senior leadership positions in a number of investment groups and has significant funds management experience in Australia leading investment in the healthcare and life sciences sector. He holds a PhD in Microbiology and a Master of Business Administration, both from the University of Melbourne.

Kevin Fischer, CPA,AGIA,ACIS
Chief Financial Officer & Company Secretary

Mr Fischer,was appointed to the role of Chief Financial Officer on November 2nd, 2015 and on January 13, 2016 was appointed Company Secretary. He has over ten years experience in senior finance roles with successful diagnostic companies, such as QIAGEN and Cellestis, and is well qualified to take on the roles of CFO and joint Company Secretary. Mr Fischer is a CPA and Chartered Secretary who has significant experience in the administration, financial management and reporting for international operations similar to those of Genetic Technologies.

Richard Allman, PhD
Honorary Fellow, Centre for Epidemiology and Biostatistics The University of Melbourne
Scientific Director

Dr Allman brings over 20 years of scientific and research experience in both the academic arena in the UK and the commercial sector in Australia. He has wide experience in research leadership, innovation management, and intellectual property strategy, covering oncology, diagnostics, and product development. Most recently he was responsible for providing scientific and technical guidance for the launch of the BREVAGen™ risk assessment test to the US market and managing both in-house research programs and external collaborative research projects, which include major academic units and commercial partners. Prior to entering the biotech sector, Dr Allman’s academic career encompassed oncology research, drug development, and assay design, with a particular interest in the linkage between onco-genetic profile and treatment response.